[
    [
        {
            "time": "2021-02-04",
            "original_text": "华大基因：向特定对象发行股票，募集资金总额约20.03亿元",
            "features": {
                "keywords": [
                    "华大基因",
                    "定增",
                    "募集资金"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因：向特定对象发行股票，募集资金总额约20.03亿元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "华大基因：1381.43万股股份将于2月9日上市",
            "features": {
                "keywords": [
                    "华大基因",
                    "股份上市"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因：1381.43万股股份将于2月9日上市",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "华大基因完成20亿元定增，高瓴资本旗下礼仁投资成第七大股东",
            "features": {
                "keywords": [
                    "华大基因",
                    "高瓴资本",
                    "定增",
                    "礼仁投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因完成20亿元定增，高瓴资本旗下礼仁投资成第七大股东",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "华大基因逆势大涨，高瓴‘小弟’成第七大股东",
            "features": {
                "keywords": [
                    "华大基因",
                    "高瓴资本",
                    "逆势大涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因逆势大涨，高瓴‘小弟’成第七大股东",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "华大基因定增募资近20亿元用于完善产业布局，高瓴参与配售",
            "features": {
                "keywords": [
                    "华大基因",
                    "定增",
                    "高瓴资本",
                    "产业布局"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因定增募资近20亿元用于完善产业布局，高瓴参与配售",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "华大基因再融资顺利落地，募集资金20.03亿元",
            "features": {
                "keywords": [
                    "华大基因",
                    "再融资",
                    "募集资金"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因再融资顺利落地，募集资金20.03亿元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "高瓴‘小弟’将成为华大基因第七大股东，规模已达400亿？",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "华大基因",
                    "第七大股东"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴‘小弟’将成为华大基因第七大股东，规模已达400亿？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "华大基因子公司新冠抗原检测产品获得CE准入资质",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠抗原检测",
                    "CE准入资质"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因子公司新冠抗原检测产品获得CE准入资质",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]